Kronos Current Deferred Revenue from 2010 to 2024

KRON Stock  USD 0.87  0.02  2.25%   
Kronos Bio Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to drop to about 6.1 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
9.6 M
Current Value
6.1 M
Quarterly Volatility
3.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kronos Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kronos Bio's main balance sheet or income statement drivers, such as Net Interest Income of 9.5 M, Interest Income of 9.5 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 9.18, Dividend Yield of 0.0 or PTB Ratio of 0.48. Kronos financial statements analysis is a perfect complement when working with Kronos Bio Valuation or Volatility modules.
  
Check out the analysis of Kronos Bio Correlation against competitors.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.

Latest Kronos Bio's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Kronos Bio over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Kronos Bio's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kronos Bio's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Kronos Current Deferred Revenue Regression Statistics

Arithmetic Mean2,648,446
Geometric Mean114,501
Coefficient Of Variation147.65
Mean Deviation3,411,394
Median9,000
Standard Deviation3,910,338
Sample Variance15.3T
Range9.6M
R-Value0.81
Mean Square Error5.7T
R-Squared0.66
Significance0.0002
Slope708,542
Total Sum of Squares214.1T

Kronos Current Deferred Revenue History

20246.1 M
20239.6 M
20219.1 M
2020M
2019818 K

About Kronos Bio Financial Statements

Kronos Bio investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Kronos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue9.6 M6.1 M

Pair Trading with Kronos Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kronos Stock

  0.71ME 23Andme HoldingPairCorr
  0.72VALN Valneva SE ADRPairCorr
  0.7JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Kronos Stock

  0.56MDGL Madrigal PharmaceuticalsPairCorr
  0.46RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Kronos Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kronos Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kronos Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kronos Bio Stock:
Check out the analysis of Kronos Bio Correlation against competitors.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.143
Quarterly Revenue Growth
0.442
Return On Assets
(0.28)
Return On Equity
(0.63)
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.